Table 2 Clinical classification of thyroid dysfunction related to PD-1 monoclonal antibody therapy in primary liver cancer
n | Hyperthyroidism (n = 20) | Hypothyroidism (n = 93) | P | t/x2/Z | |
|---|---|---|---|---|---|
Classification by causes (n,%) | |||||
Primary thyroid dysfunction | 93 | 19(95.0) | 74(79.6) | 0.188 | 1.735 |
Secondary thyroid dysfunction | 20 | 1(5.0) | 19(20.4) | ||
Classification by symptom (n,%) | |||||
Clinical thyroid dysfunction | 42 | 14(70.0) | 28(31.2) | 0.001 | 11.217 |
Subclinical thyroid dysfunction | 71 | 6(30.0) | 65(68.8) | ||
Classification by adverse reaction severity (n,%) | 0.328 | 2.230 | |||
Grade 1 | 61 | 8(40.0) | 53(57.0) | ||
Grade 2 | 42 | 9(45.0) | 33(35.5) | ||
Grade 3 | 10 | 3(15.0) | 7(7.5) | ||
Grade 4 | 0 | 0(0.0) | 0(0.0) | ||
Grade 5 | 0 | 0(0.0) | 0(0.0) |